Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$0.79 -1.6%	$0.82	$0.55 ▼ $1.66	$102.04M	0.92	775,605 shs	723,543 shs
KALA KALA BIO	$4.04 -4.7%	$3.78	$2.92 ▼ $11.20	$26.07M	-1.98	95,793 shs	23,275 shs
THTX Theratechnologies	$2.53 +1.2%	$2.63	$1.12 ▼ $3.13	$116.33M	0.6	820,123 shs	179,134 shs
ZNTL Zentalis Pharmaceuticals	$1.30 -5.8%	$1.34	$1.01 ▼ $5.44	$93.54M	1.61	1.45 million shs	1.29 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	0.00%	-4.88%	-9.18%	+4.80%	-29.46%
KALA KALA BIO	0.00%	-6.05%	-1.22%	-41.62%	-22.31%
THTX Theratechnologies	0.00%	+2.02%	-2.32%	+60.13%	+91.67%
ZNTL Zentalis Pharmaceuticals	0.00%	-2.99%	+4.84%	-31.94%	-68.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATOS Atossa Genetics	1.1547 of 5 stars	3.7	0.0	0.0	0.0	0.6	1.7	0.0
KALA KALA BIO	2.4364 of 5 stars	3.5	1.0	0.0	4.4	0.0	0.8	0.6
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	2.0415 of 5 stars	3.3	2.0	0.0	0.0	2.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	3.33	Buy	$6.17	680.59% Upside
KALA KALA BIO	3.00	Buy	$13.50	234.16% Upside
THTX Theratechnologies	4.00	Strong Buy	N/A	N/A
ZNTL Zentalis Pharmaceuticals	2.50	Moderate Buy	$8.37	543.59% Upside

Current Analyst Ratings Breakdown

Latest KALA, THTX, ATOS, and ZNTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.25 ➝ $7.50
6/5/2025	ATOS Atossa Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$4.00
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/15/2025	ZNTL Zentalis Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
5/15/2025	ZNTL Zentalis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/21/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.25
4/11/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/4/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/28/2025	ZNTL Zentalis Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
3/27/2025	ZNTL Zentalis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$0.57 per share	N/A
KALA KALA BIO	$3.89M	6.70	N/A	N/A	$2.02 per share	2.00
THTX Theratechnologies	$85.87M	1.35	N/A	N/A	($0.55) per share	-4.60
ZNTL Zentalis Pharmaceuticals	$67.43M	1.39	N/A	N/A	$4.73 per share	0.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$25.50M	-$0.21	N/A	N/A	N/A	N/A	-33.90%	-31.53%	8/11/2025 (Estimated)
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)
THTX Theratechnologies	-$8.31M	-$0.08	N/A	36.14	N/A	-4.18%	N/A	-0.37%	7/9/2025 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$165.84M	-$3.13	N/A	N/A	N/A	N/A	-65.48%	-51.05%	8/8/2025 (Estimated)

Latest KALA, THTX, ATOS, and ZNTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ZNTL Zentalis Pharmaceuticals	-$0.67	-$0.67	N/A	-$0.67	N/A	N/A
5/13/2025	Q1 2025	ATOS Atossa Genetics	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A
3/28/2025	Q4 2024	KALA KALA BIO	-$2.28	-$1.74	+$0.54	-$1.74	N/A	N/A
3/26/2025	Q4 2024	ZNTL Zentalis Pharmaceuticals	-$0.75	-$0.66	+$0.09	-$0.66	N/A	$26.90 million
3/25/2025	Q4 2024	ATOS Atossa Genetics	-$0.0633	-$0.05	+$0.0133	-$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	12.67	12.67
KALA KALA BIO	3.19	1.99	1.99
THTX Theratechnologies	N/A	1.08	0.88
ZNTL Zentalis Pharmaceuticals	N/A	6.94	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
KALA KALA BIO	24.61%
THTX Theratechnologies	N/A
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	7.60%
KALA KALA BIO	8.32%
THTX Theratechnologies	N/A
ZNTL Zentalis Pharmaceuticals	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	8	129.17 million	119.35 million	Optionable
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable
ZNTL Zentalis Pharmaceuticals	160	71.95 million	70.59 million	Optionable

KALA, THTX, ATOS, and ZNTL Headlines

Recent News About These Companies

Zentalis Pharmaceuticals shareholders elect three directors at annual meeting

June 21 at 12:16 AM | investing.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages

June 17, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Bank of America Corp DE

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Sells 291,801 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

June 3, 2025 | marketbeat.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Two Sigma Advisers LP

May 29, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock Holdings Lessened by Woodline Partners LP

May 27, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by Analysts

May 25, 2025 | marketbeat.com

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025 | globenewswire.com

First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer

May 3, 2025 | curetoday.com

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | globenewswire.com

Scott Dunseth Myers Purchases 21,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

May 1, 2025 | insidertrades.com

Zentalis shares insights on cancer research at AACR

April 29, 2025 | investing.com

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

April 28, 2025 | globenewswire.com

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

April 23, 2025 | globenewswire.com

Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 8.97%

April 10, 2025 | aaii.com

Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 12.58%

April 2, 2025 | aaii.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2025 | globenewswire.com

Stifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)

March 27, 2025 | markets.businessinsider.com

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

March 26, 2025 | globenewswire.com

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

March 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA, THTX, ATOS, and ZNTL Company Descriptions

Atossa Genetics NASDAQ:ATOS

$0.79 -0.01 (-1.64%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.81 +0.02 (+3.04%)

As of 06/20/2025 07:57 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

KALA BIO NASDAQ:KALA

$4.04 -0.20 (-4.72%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.12 +0.08 (+1.98%)

As of 06/20/2025 05:01 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Theratechnologies NASDAQ:THTX

$2.53 +0.03 (+1.20%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.57 +0.04 (+1.58%)

As of 06/20/2025 07:13 PM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.30 -0.08 (-5.80%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.30 +0.00 (+0.31%)

As of 06/20/2025 07:50 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time